The Digitization Paradox: Why 92% of CDMOs Face Digital Requirements — and 0% Are Fully There

The CDMO industry is on a tear. The global contract development and manufacturing market sits at $259 billion and is projected to grow at a 6.3% compound annual growth rate through 2031.¹ Demand from cell and gene therapies, the GLP-1 manufacturing surge, and a geopolitical reshuffling of global supply chains is pushing outsourcing to new heights. Industry sentiment reflects it: more than half (60%) of all industry stakeholders describe themselves as "highly positive" on contract services growth², and more than 75% of life sciences executives feel confident about their own organization's financial trajectory.³

On the surface, the 2026 contract development and manufacturing organization (CDMO) industry trends tell a success story. But underneath that momentum lives a number that should give every contract manufacturer pause.

92% of CDMOs are now facing explicit digital requirements in sponsor contract negotiations. And 0% report full digital integration with their sponsors.⁴

That's the digitization paradox widely affecting the current state of CDMOs in life sciences. And it's quietly reshaping how sponsors choose partners, how contracts get written, and ultimately, who wins business in the years ahead.

What You'll Find in the 2026 CDMO Industry Trends Brief

State of the CDMO Industry 2026: The Digitization Imperative goes well beyond the headline stats to give contract development and manufacturing organizations a practical lens for navigating this moment. Inside, you'll find:

• The macro forces reshaping outsourcing demand and the data behind each one.
• A digital maturity framework with an honest picture of where most CDMOs actually land.
• A deep-dive on AI underperformance and the infrastructure decisions that change the outcome.
• What sponsors are requiring in contracts now and how to get ahead of rising digital expectations.
• The operational investments delivering the strongest ROI across the CDMO industry right now.

The Forces Reshaping CDMO Outsourcing Demand

The growth wave isn't random. It's powered by converging structural forces that show no sign of slowing. Here's what's driving the current moment for CDMOs in life sciences:

• Cell and gene therapies (CGT): Continued CGT growth demands specialized, scalable manufacturing and complex supply chains that most sponsors prefer to outsource rather than build in-house.
• The GLP-1 revolution: Unprecedented demand for peptide-based treatments has created capacity crunches across the industry.
• Geopolitical dynamics: BIOSECURE Act-related concerns are actively redirecting outsourcing flows and accelerating supply chain diversification.
• The partnership evolution: What was once a transactional arrangement has become a fully strategic relationship, with sponsors now writing digital transparency expectations directly into contracts.

That last point is where the CDMO trends story gets genuinely complicated.

The Digital Readiness Gap Across the CDMO Industry

The numbers tell a story the CDMO industry has been slow to confront head-on. According to MasterControl's own research into digital maturity across contract development and manufacturing organizations:

• 92% of CDMOs are facing digital requirements in sponsor negotiations.
• 0% report full digital integration with their sponsors.
• 60% remain in the early stages of digital adoption.

How is it possible to have near-universal digital requirements and zero full adoption simultaneously? It comes down to a distinction the industry tends to blur — the difference between digitization and digital transformation:

• Digitization = Converting paper records to electronic files, purchasing software, replacing manual logbooks with database entries — a format change.
• Digital transformation = Fundamentally redesigning operations around data: single sources of truth, real-time data flow, and systems that actually integrate — a complete operational re-engineering.

Most contract manufacturers have accomplished the first while believing they've achieved the second. Sponsors, increasingly, are noticing the gap and writing their expectations into contracts accordingly.

MasterControl's new trends brief maps the full digital maturity spectrum across the CDMO industry and shows, honestly, where most organizations currently stand. It's a picture worth seeing before your next sponsor conversation.

Benchmark where your organization really stands on the digital maturity curve. Take the digital maturity assessment today.

The AI Disconnect Holding CDMOs Back

Most CDMOs today consider themselves AI-forward. The data tells a more complicated story.⁵

• 96%-plus of life sciences organizations have deployed generative AI tools.
• Only 11% report experiencing significant AI impact.
• 42% of pharmaceutical AI projects fail to meet their ROI expectations.

The leading cause of AI underperformance? It's rarely the AI itself. Inadequate data quality and availability is cited by 55% of organizations as the primary reason AI pilots fail.⁶ Add the 62% of digital initiatives that are actively hindered by data silos, and a pattern emerges.⁷

AI is a data amplifier. Feed it clean, connected, structured data from integrated systems, and it becomes a genuine business advantage. Feed it fragmented data from disconnected systems with inconsistent standards, and you get expensive noise.

The CDMOs seeing real ROI from AI aren't just buying better tools — they've built a smarter foundation first. The trends brief goes deep on what separates those organizations from the rest, and it reframes the AI investment conversation in a way that's more useful than most industry commentary.

Find out what separates CDMOs making AI work from those still chasing ROI. Download the State of the CDMO Industry 2026 brief.

What CDMOs Stand To Potentially Lose

Digital maturity has become a business development strategy, not just an IT project.

The strategic partnership model now defining sponsor-CDMO relationships requires transparency and operational integration that paper-based and disconnected systems can't deliver. Organizations that haven't built the right foundation risk losing deals not on price or capacity, but on digital readiness alone.

The flip side of that equation is compelling. Organizations that have invested in proper data foundations are already seeing the payoff from Quality 4.0 initiatives:

• 25%-45% reductions in lab operational costs.
• Up to 70% shorter batch review times.
• Payback periods of just 1-3 years.⁸

The contract manufacturers winning new business in 2026 aren't necessarily the biggest players. They're the ones whose digital foundation makes them genuinely easy to partner with.

The Bottom Line for CDMOs

The 2026 CDMO industry trends are clear: the market opportunity is enormous, but capturing it increasingly demands more than capacity. Digital readiness has become the deciding factor in sponsor decisions, partnership expansions, and long-term competitive positioning.

The gap between where most contract development and manufacturing organizations think they are — and where they actually are — is real. So is the opportunity for those who close it.

Don't navigate the contract manufacturing market without the data you need. Download State of the CDMO Industry 2026: The Digitization Imperative — free today.

What CDMOs Should Do Next To Get Ahead

• Subscribe to the GxP Lifeline newsletter to access other informative articles like this.
• Take our free digital maturity assessment to discover how your organization currently competes within the industry and the actionable steps to get ahead.
• Contact us to get answers for your software, quality, and compliance questions.

Sources

1. “Contract Development And Manufacturing Organization (CDMO) Market - Global Industry Analysis,” Mordor Intelligence, 2025.
2. “CDMOs eye industrywide growth in 2025 as many spurn BIOSECURE Act, CPHI research shows,” by Fraiser Kansteiner, Fierce Pharma, Sept. 30, 2024.
3. “2026 Life Sciences Executive Outlook,” Deloitte Center for Health Solutions, 2025.
4. “AI + Digital Maturity in Contract Development and Manufacturing,” MasterControl Research Report, 2024. Survey of 50-plus CDMO organizations globally.
5. “The Connectivity Crisis Blocking AI Deployment in Life Sciences Manufacturing,” MasterControl Research Report, 2025. Survey of 300 quality and manufacturing professionals, conducted November 5-21, 2025.
6. “The 2026 AI power shift: Enabling the translational gap with AI,” Drug Discovery News, Jan. 26, 2026.
7. “Digital Transformation In The Pharma Industry Statistics: Market Data Report 2026,” GitNux, Feb. 13, 2026.
8. “Quality 4.0 in Pharma: A 2026 ROI & Economic Analysis,” IntuitionLabs, 2026.